TargeTrust Biotech. Ltd.

Real Early Cancer Screening, Detecting Cancer Therapy Resistance & Guiding Precision Dosing, in Real-Time 

Product Value

      Our product can greatly reduce the global cancer problem. The world’s only product to:

1. Screen real early cancer to cut tumor away, making cancer cured easily.

2. Detect cancer therapy resistance in real-time. Guide correct therapy. Prevent patients from taking ineffective drugs.

3. Guide precision dosing in real-time. Reduce drug side-effects in cancer therapy.

4. Detect early cancer relapse, to timely treat it.

5. Make real-time cancer action detection possible.

6. Applicable to all cancer types and all therapy methods.

Problems in Caner Therapy:

1. Most cancers are detected too late by current methods: Render cancer hard to treat.

2. Therapy resistance detected too late by current methods:30～70% treating drugs become ineffective; patients take ineffective drugs; delay therapy; hightly lethal.

3. Drug side-effects unsolvable with current methods: Patients uncomfortable; may disrupt therapy; cause other diseseases; sometime lethal.

4. Current methods (CT, MRI, PET, CTC, ctDNA common liquid biopsy, traditional biomarkers, NGS, CancerSEEK, Grail MCED Test) assay cancer and cancer therapy response at cancer progression stage (increased tumor size, tumor invade other organs), these take many months; too late; delay therapy. The early cancer detection rates by current methods are low, most cancers are detected too late.

 Our Solution:    

     Tumor signal transductions stimulate cancer progression, it takes time only 1 hour and circulates. We creates a novel medical field "Tumor Signal Transduction-Liquid Biopsy" to assay tumor signals in blood. It is the world's only method to detect emerging cancer formation, cancer progression, cancer relapse, therapy resistance, and drug precision dosing, in real-time. It makes real-time cancer action detection possible. 

Our product can screen real early cancer, to cut tumors away, making cancer cured easily 

Competitive Analysis

1. Grail MCED Test and CancerSEEK  can detect 50 or 8 cancer types by assaying blood ctDNA. The sensitivity for stage I cancer detection range from 12% ～ 39% .

2.  Cancer assay with CancerSEEK and Grail MCED Test  are too late and delay therapy, because presence or increased ctDNA (circulating tumor DNA) indicate tumor growth, invasion, and therapy resistance occurred a long time ago. 

3. CancerSEEK and Grail MCED Test are a lab service, not a sellable product, thus are not widely available. 

Other Projects

## Tumor biomarker p-CSE1L:

(1) It is highly expressed in most cancer types.

(2) It is a microvesicle membrane protein accumulated in tumor.

(3) Cancers have oncogenes which result in CSE1L phosphorylation.

(4) Tumor cells express oncogene thus have high phospho-CSE1L; normal cells don’t express oncogene, p-CSE1L is undetectable

## Our invention can be used in:

1. Targeted contrast agent for image-guided precision cancer surgery

2. Targeted imaging agent for precise radiotherapy

3. Antibody-drug conjugates

4. Targeted magnetic hyperthermia cancer therapy

Contact: jiangmwd@gmail.com